

ORIGINAL STUDY

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms

Michael R. McClung, MD,^{1,2} Risa Kagan, MD, NCMP,³ Shelli Graham, PhD,⁴ Brian Bernick, MD,⁴ Sebastian Mirkin, MD,⁴ and Ginger Constantine, MD⁵

Abstract

Objective: To evaluate bone turnover markers (BTM) in the REPLENISH trial (NCT01942668).

Methods: REPLENISH evaluated oral estradiol/progesterone (E2/P4) for the treatment of moderate to severe vasomotor symptoms (VMS) in postmenopausal women with a uterus. Eligible women for this analysis had ≥ 50 moderate to severe VMS/wk, were < 5 years since last menstrual period, and had BTM measurements at baseline, and months 6 and 12. Percent changes for three BTM (bone-specific alkaline phosphatase [BSAP], C-terminal telopeptide of type I collagen [CTX-1], and N-terminal propeptide of type I procollagen [PINP]) assessed by immunoassay methods were evaluated from baseline to months 6 and 12 for the 1 mg E2/100 mg P4, 0.5 mg E2/100 mg P4, and placebo groups.

Results: A total of 157 women (40-61 y, 69% White) were analyzed. Mean baseline values ranged from 14.0 to 14.3 U/L for BSAP, 0.34 to 0.39 ng/mL for CTX-1, and 76.9 to 79.3 ng/mL for PINP. Mean differences in percent change from baseline for both E2/P4 doses versus placebo significantly decreased at months 6 and 12 and ranged from -8% to -16% for BSAP (all, $P < 0.05$), -30% to -41% for CTX-1 (all, $P \leq 0.001$), and -14% to -29% for PINP (all, $P < 0.01$).

Conclusions: REPLENISH data provide support for a potential skeletal benefit of E2/P4 when it is used for the treatment of moderate to severe VMS. Further studies are warranted.

Key Words: Bone markers – BSAP – CTX-1 – Estradiol – PINP – Progesterone – Vasomotor symptoms.

Video Summary: <http://links.lww.com/MENO/A894>.

Bones are constantly being remodeled in a tightly coupled balance between resorption and formation processes, which are necessary for the maintenance and overall health of bone.¹ When this balance becomes uncoupled, such that resorption exceeds formation, the net bone loss can result in the disordered skeletal architecture of osteoporosis. As key modulators of bone metabolism, estrogens play an important role in the growth and maturation of bone and in the regulation of bone turnover in adults. When

levels of circulating estrogens decline during menopause, bone resorption increases, leading to reduced bone mineral density (BMD) and increased risk of osteoporotic fractures.² In menopausal women with vasomotor symptoms (VMS), hormone therapy can effectively treat their symptoms and can also reduce bone turnover and prevent bone loss.^{3,4}

The REPLENISH trial (NCT01942668) was a phase 3 study that evaluated four doses of 17 β -estradiol and progesterone (E2/P4) combination capsules (TX-001HR) for the treatment of

Received August 18, 2021; revised and accepted October 11, 2021.

From the ¹Oregon Osteoporosis Center, Portland, OR; ²Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, VIC, Australia; ³University of California, San Francisco and Sutter East Bay Medical Foundation, Berkeley, CA; ⁴TherapeuticsMD, Boca Raton, FL; and ⁵EndoRheum Consultants, LLC, Malvern, PA.

Funding/support: TherapeuticsMD sponsored the study and provided support for the medical writing assistance of Dominique Verlaan, PhD (Precise Publications, LLC).

Financial disclosures/conflicts of interest: M.R.M. consults for Amgen and Myovant; and has served on the speaker's bureau of Amgen. R.K. consults for Amgen, Astellas, and TherapeuticsMD; and has served on the speaker's bureau of TherapeuticsMD. S.G., B.B., and S.M. are employees of TherapeuticsMD with stock/stock options. G.C. consults to multiple pharmaceutical companies including but not

limited to TherapeuticsMD and has stock options from TherapeuticsMD.

These data were published in an abstract submitted to the Endocrine Society 2020 (June 2020; online meeting) but was not presented.

Supplemental digital content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's Website (www.menopause.org).

Address correspondence to: Michael R. McClung, MD, Oregon Osteoporosis Center, 2881 NW Cumberland Road, Portland, OR 97210.

E-mail: mmclung.ooc@gmail.com

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

menopausal, moderate to severe VMS in women with a uterus.⁵ Statistically significant improvements in the frequency and severity of moderate to severe VMS were observed with the two highest E2/P4 (1/100 and 0.5/100 [mg/mg]) doses, meeting the study's coprimary endpoints.⁵ The 1 mg E2/100 mg P4 dose was approved by the Food and Drug Administration for the treatment of moderate to severe VMS in women with a uterus.⁶ The 0.5/100 E2/P4 dose is currently under review at the Food and Drug Administration for the same indication.

Bone remodeling can be evaluated with bone turnover marker (BTM) assays, which measure collagen breakdown products and other molecules released from osteoclasts and osteoblasts during the process of bone resorption and formation.^{7,8} High bone turnover in postmenopausal women, as assessed by these BTMs, is associated with bone loss, while interventions that reduce BTMs lead to preservation or improvement of BMD. In this post hoc study of the REPLENISH trial, the objective was to evaluate BTM changes in postmenopausal women treated with the 1/100 and 0.5/100 E2/P4 doses compared with those treated with placebo.

METHODS

Study design

The REPLENISH trial (NCT01942668) was a 12-month, phase 3, multicenter, randomized, placebo-controlled, double-blind study that evaluated TX-001HR for the treatment of moderate to severe VMS in postmenopausal women with a uterus.⁵ Description of the study design has been previously published.⁵ Briefly, healthy postmenopausal women between the ages of 40 and 65 years, with an intact uterus, body mass index ≤ 34 kg/m², and seeking treatment for VMS associated with menopause were eligible to enroll in the study. Postmenopausal status was defined as spontaneous amenorrhea for at least 12 months or a screening serum follicle-stimulating hormone level greater than 40 mIU/mL for at least 6 months, or bilateral oophorectomy at least 6 weeks prior to screening. Major exclusion criteria included recent use of medications that could alter the activity of estrogen or progesterone, having a contraindication or allergy to estrogen and/or progesterone, and heavy smoking (≥ 15 cigarettes/d). Women could not be enrolled in the study if they had a history of thromboembolic disorder, coronary artery or cerebrovascular disease, chronic liver or kidney disorder, diabetes, or other endocrinological diseases. Concomitant medications that could affect bone turnover such as estrogens, progestogens, and SERMs were not allowed; however, women could have been using these products prior to the study, which may impact bone turnover. Use of bone-specific agents, such as alendronate and risedronate, was not an exclusion criterion. All participants gave written informed consent.

Women with moderate to severe hot flashes (≥ 7 /d or ≥ 50 /wk) at baseline were included in a VMS substudy and were randomized 1:1:1:1 to daily E2/P4 (mg/mg) of 1/100, 0.5/100, 0.5/50, or 0.25/50, or placebo for 12 months. The remaining participants were randomized 1:1:1:1 to the four active doses. The safety

population included all women who took at least one dose of the study drug for analysis of drug safety. The trial was conducted at 117 US sites in accordance with Good Clinical Practice; the study protocol was approved by a central or local institutional review board at each study site.

The REPLENISH primary efficacy and safety endpoints have been previously described.^{5,9} Primary efficacy endpoints were changes in the frequency and severity of moderate to severe VMS from baseline to weeks 4 and 12 in the VMS substudy.⁵ The primary safety endpoint was the incidence of endometrial hyperplasia in women who completed the 12-month treatment.⁹

Bone turnover marker assessments

Serum BTMs were assessed from fasting blood samples obtained at baseline, month 6 and month 12. The analysis was restricted to women included in the VMS substudy with < 5 years since their last menstrual period and BTM measurements available for all timepoints. Women with < 5 years since their last menstrual period were chosen as they would likely have the greatest change in their BTMs. The markers of bone formation, bone-specific alkaline phosphatase (BSAP, MicroVue, Quidel, San Diego, CA) and N-terminal propeptide of type I procollagen ([P1NP], Abbexa, Houston, TX), and the marker of bone resorption, C-terminal telopeptide of type I collagen (CTX-1, Serum CrossLaps, US Immunodiagnostic Systems, Gaithersburg, MD) were assessed by enzyme-linked immunoassay methods in batch assays by Syneos Health (Morrisville, NC). Samples were blinded to Syneos Health employees. The coefficient of interassay variability was $\leq 7.6\%$ for BSAP, $< 12\%$ for P1NP, and $\leq 10.9\%$ for CTX-1. The BTMs were analyzed in September 2019 from blood samples collected between 2013 and 2016; samples were frozen to -80°C during storage. Long-term stabilities at $-20^\circ\text{C}/-80^\circ\text{C}$ were validated to 458 days for BSAP in matrix and to 444 days for CTX-1 in matrix. No long-term stabilities were demonstrated for the P1NP assays.

Statistical analysis

Percent changes from baseline to months 6 and 12 for each BTM marker were calculated and compared between the 1/100 and 0.5/100 E2/P4 doses and placebo. *P* values were calculated for between-group comparisons using the mixed model for repeated measures with treatment, visit, and treatment-by-visit interaction as factors; baseline as covariate; and subject as repeated measure unit. Statistical analysis was performed with SAS v 9.2 or higher (SAS Institute, Cary, NC).

RESULTS

Demographics and disposition

Of the 1,260 women in the REPLENISH trial treated with 1/100 E2/P4, 0.5/100 E2/P4, or placebo, a total of 157 women (with < 5 y since their last menstrual period and BTM measurements at all timepoints) were included in this post hoc analysis (56 women each from the 1/100 and 0.5/100 E2/P4 groups and 45 women from the placebo group).

TABLE 1. Demographic and baseline characteristics

	1 mg E2/100 mg P4 (n = 56)	0.5 mg E2/100 mg P4 (n = 56)	Placebo (n = 45)
Age, y	52.2 ± 3.8	52.3 ± 3.1	52.6 ± 4.1
Range	40-61	45-60	45-60
Race, n (%)			
White	39 (70)	36 (64)	33 (73)
Black or African American	17 (30)	19 (34)	12 (27)
Other ^a	0	1 (2)	0
Years since menopause, y	2.0 ± 1.3	2.4 ± 1.4	2.4 ± 1.1
Range	0.5-4.9	0.5-4.9	0.6-4.8
BMI, kg/m ²	26.3 ± 3.5	27.9 ± 4.4	27.0 ± 4.1
Range	19-33	18-35	19-34
BMI tertile, n (%)			
<25 kg/m ²	22 (39)	17 (30)	16 (36)
25 to <30 kg/m ²	24 (43)	16 (29)	19 (42)
≥30 kg/m ²	10 (18)	23 (41)	10 (22)
Alcohol history, n (%)			
Current	30 (54)	41 (73)	28 (62)
Former	7 (13)	3 (5)	3 (7)
Never	19 (34)	12 (21)	14 (31)
Smoking history, n (%)			
Current	11 (20)	17 (30)	8 (18)
Former	16 (29)	12 (21)	11 (24)
Never	29 (52)	27 (48)	26 (58)
Estradiol, pg/mL	6.8 ± 6.8	8.7 ± 9.9	6.5 ± 4.8
Median	4.6	5.4	4.6
Estrone, pg/mL	24.2 ± 17.8	25.9 ± 11.3	25.7 ± 9.2
Median	19.9	22.4	23.9
BSAP, U/L	14.3 ± 4.0	14.3 ± 4.5	14.0 ± 4.6
Median	13.7	12.8	12.7
P1NP, ng/mL	79.3 ± 21.8	77.9 ± 24.9	76.9 ± 23.7
Median	75.0	68.4	73.6
CTX-1, ng/mL	0.39 ± 0.15	0.38 ± 0.18	0.34 ± 0.14
Median	0.35	0.34	0.33

Data expressed as mean ± SD, unless otherwise stated.

BMI, body mass index; BSAP, bone-specific alkaline phosphatase; CTX-1, C-terminal telopeptide of type I collagen; E2, estradiol; P1NP, N-terminal propeptide of type I procollagen; P4, progesterone.

^aOther could include American Indian/Alaska Native, Native Hawaiian/Pacific Islander, and Unknown.

The majority of women were White (69%) with a mean age of 52 years and BMI of 26 to 28 kg/m² (Table 1). Baseline estradiol levels were slightly numerically higher for women in the 0.5/100 E2/P4 group (8.7 pg/mL) versus the 1/100 E2/P4 (6.8 pg/mL) and placebo (6.5 pg/mL) groups. Mean baseline value ranges were 14.0 to 14.3 U/L for BSAP, 76.9 to 79.3 ng/mL for P1NP, and 0.34 to 0.39 ng/mL for CTX-1. None of the women reported using medications to treat osteopenia or osteoporosis.

Bone turnover markers

A total of 443 BSAP samples were analyzed in 15 different analytical runs, 443 P1NP samples in 18 different analytical runs, and 443 CTX-1 samples in 14 separate analytical runs. For all three BTMs, mean differences in percent changes from baseline with both E2/P4 doses versus placebo significantly decreased at months 6 and 12 (Fig. 1). No significant differences were observed between the two E2/P4 doses at months 6 and 12, except for the P1NP marker at month 12 ($P < 0.016$). With E2/P4, mean differences from placebo from baseline to months 6 and 12 ranged from -8% to -16% for BSAP, from -14% to -29% for P1NP, and -30% to -41% for CTX-1 (Table 2). Reductions for BSAP and P1NP appeared to have a dose-dependent pattern, with the 1/100 E2/P4 dose reducing BTMs the most.

DISCUSSION

Hormone therapy is the most effective treatment for moderate to severe postmenopausal vasomotor symptoms, but it has also been shown to prevent bone loss and fracture.¹⁰⁻¹² In the REPLENISH trial, markers of both bone formation and resorption were significantly reduced from baseline for up to 12 months with E2/P4 (1/100 and 0.5/100) compared with placebo.

Markers of bone turnover are valuable for assessing the dynamic nature of bone remodeling in response to antiremodeling therapies.¹³ Reductions in bone turnover with estrogens, bisphosphonates, and denosumab have been associated with preservation or increases in BMD in young postmenopausal women with low bone mass.¹⁴⁻¹⁸ Short-term changes in BTMs are predictive of longer-term increases in BMD.¹⁹ The responses of BTM to antiremodeling therapies in women with postmenopausal osteoporosis have also been shown to be predictors of vertebral but not nonvertebral fracture outcomes.^{20,21} In the Foundation for the National Institutes of Health Bone Quality meta-regression of 14 randomized, placebo-controlled fracture endpoint trials with BTM data, strong relationships were observed between treatment-related BSAP or P1NP changes and vertebral fracture risk reduction.²⁰ Treatment-associated reductions in BSAP levels compared with placebo of 12% and 30% correlated with reductions in

TX-001HR EFFECTS ON BONE TURNOVER MARKERS




FIG. 1. Percent changes from baseline in (A) BSAP, (B) P1NP, and (C) CTX-1. ^a*P* < 0.05; ^b*P* < 0.01; ^c*P* < 0.001 versus placebo; ^d*P* < 0.05 versus 0.5 mg E2/100 mg P4; ^e*n* = 46 for P1NP and CTX-1; ^f*n* = 53 for CTX-1. BSAP, bone-specific alkaline phosphatase; CTX-1, C-terminal telopeptide of type I collagen; E2, estradiol; P1NP, N-terminal propeptide of type I procollagen; P4, progesterone.

TABLE 2. Changes from baseline in bone turnover markers with E2/P4 versus placebo

	1 mg E2/100 mg P4 (n = 56)		0.5 mg E2/100 mg P4 (n = 56)		Placebo (n = 45)	
	n	Mean ± SD	n	Mean ± SD	n	Mean ± SD
BSAP, U/L						
Baseline	56	14.34 ± 4.5	56	14.29 ± 4.5	45	14.05 ± 4.6
Month 6	54	12.76 ± 3.7	54	13.26 ± 4.3	43	14.16 ± 4.8
Month 12	47	12.62 ± 3.9	48	12.62 ± 3.4	38	14.67 ± 5.0
LSM % change from placebo						
Month 6	54	-12.5 ^a	54	-8.1 ^b		
Month 12	47	-16.1 ^a	48	-8.3 ^c		
P1NP, ng/mL						
Baseline	56	79.32 ± 21.8	56	77.88 ± 24.9	45	76.89 ± 23.7
Month 6	54	59.35 ± 17.6	54	63.94 ± 23.3	43	79.85 ± 25.0
Month 12	46	53.66 ± 18.1	48	60.57 ± 19.2	38	75.40 ± 26.8
LSM % change from placebo						
Month 6	54	-28.6 ^a	54	-23.0 ^a		
Month 12	46	-28.2 ^a	48	-14.2 ^c		
CTX-1, ng/mL						
Baseline	55	0.390 ± 0.15	56	0.384 ± 0.18	45	0.344 ± 0.14
Month 6	53	0.287 ± 0.22	53	0.279 ± 0.14	43	0.358 ± 0.14
Month 12	46	0.248 ± 0.10	48	0.262 ± 0.12	38	0.374 ± 0.14
LSM % change from placebo						
Month 6	52	-29.5 ^c	53	-30.1 ^a		
Month 12	46	-41.1 ^a	48	-38.1 ^a		

BSAP, bone-specific alkaline phosphatase; CTX-1, C-terminal telopeptide of type I collagen; E2, estradiol; LSM, least square mean; P1NP, N-terminal propeptide of type I procollagen; P4, progesterone.
^a*P* < 0.001 versus placebo. ^b*P* < 0.05. ^c*P* < 0.01.

risk of vertebral fracture of 30% and 65%, respectively, while a 22% reduction in PINP compared with placebo was associated with a 30% reduction in vertebral fracture risk. These percent changes in BTMs are similar to those observed in our study, suggesting that the reductions in BSAP and PINP with 1/100 or 0.5/100 E2/P4 may translate into improved bone strength and reduced fracture risk.

Limitations of these analyses include the fact that BTM assessments were post hoc analyses of the REPLENISH trial and not one of the primary endpoints. Furthermore, we did not have any measurements of BMD nor morphometric fracture data from patients, which would have been useful to determine the effects of E2/P4 on BMD and fracture risk. Finally, BTMs in blood samples may have been degraded during long-term storage. Nevertheless, the current analysis suggests that significant reductions in bone turnover occur with E2/P4, implying a skeletal benefit when E2/P4 is used to treat moderate to severe VMS. Further studies will be needed to better our understanding of the effects of E2/P4 on bone.

CONCLUSION

In the REPLENISH trial, treatment of postmenopausal women with a uterus for moderate to severe VMS with 1/100 E2/P4 or 0.5/100 E2/P4 was associated with reduced markers of bone turnover. These results suggest that postmenopausal women with a uterus who are taking E2/P4 for their moderate to severe vasomotor symptoms may have an additional skeletal benefit while using E2/P4. Further studies are warranted to confirm these results.

Acknowledgments: The authors would like to acknowledge the statistical analysis by Chao Wang, and the medical writing assistance provided by Dominique Verlaan, PhD of Precise Publications, LLC, which was supported by TherapeuticsMD.

REFERENCES

1. Hadjidakis DJ, Androulakis II. Bone remodeling. *Ann N Y Acad Sci* 2006;1092:385-396. doi: 10.1196/annals.1365.035.
2. Cauley JA. Estrogen and bone health in men and women. *Steroids* 2015;99:11-15. doi: 10.1016/j.steroids.2014.12.010.
3. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. *Menopause* 2017;24:728-753. doi: 10.1097/gme.0000000000000921.
4. Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-term hormone therapy for perimenopausal and postmenopausal women. *Cochrane Database Syst Rev* 2017;1:Cd004143. doi: 10.1002/14651858.CD004143.pub5.
5. Lobo RA, Archer DF, Kagan R, et al. A 17 β -estradiol-progesterone oral capsule for vasomotor symptoms in postmenopausal women: a randomized controlled trial. *Obstet Gynecol* 2018;132:161-170. doi: 10.1097/AOG.0000000000002645.
6. Bijuva® (estradiol and progesterone) capsules, for oral use Prescribing Information. Boca Raton, FL: TherapeuticsMD; 2019.
7. Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. *Lancet Diabetes Endocrinol* 2017;5:908-923. doi: 10.1016/S2213-8587(17)30184-5.
8. Jain S, Camacho P. Use of bone turnover markers in the management of osteoporosis. *Curr Opin Endocrinol Diabetes Obes* 2018;25:366-372. doi: 10.1097/med.0000000000000446.
9. Mirkin S, Goldstein SR, Archer DF, Pickar JH, Graham S, Bernick B. Endometrial safety and bleeding profile of a 17 β -estradiol/progesterone oral softgel capsule (TX-001HR). *Menopause* 2020;27:410-417. doi: 10.1097/gme.0000000000001480.
10. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA* 2003;290:1729-1738. doi: 10.1001/jama.290.13.1729.
11. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. *JAMA* 2004;291:1701-1712. doi: 10.1001/jama.291.14.1701.
12. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. *J Bone Miner Res* 2006;21:817-828. doi: 10.1359/jbmr.060312.
13. Brown JP, Albert C, Nassar BA, et al. Bone turnover markers in the management of postmenopausal osteoporosis. *Clin Biochem* 2009;42:929-942. doi: 10.1016/j.clinbiochem.2009.04.001.
14. Writing Group for the Pepi Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. *JAMA* 1996;276:1389-1396.
15. Ravn P, Bidstrup M, Wasnich RD, et al. Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, controlled trial. *Ann Intern Med* 1999;131:935-942. doi: 10.7326/0003-4819-131-12-199912210-00005.
16. Greenwald MW, Gluck OS, Lang E, Rakov V. Oral hormone therapy with 17 β -estradiol and 17 β -estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. *Menopause* 2005;12:741-748. doi: 10.1097/01.gme.0000184425.73567.12.
17. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou CL. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. *Obstet Gynecol* 2009;114:999-1007. doi: 10.1097/AOG.0b013e3181bdce0a.
18. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. *J Clin Endocrinol Metab* 2008;93:2149-2157. doi: 10.1210/jc.2007-2814.
19. Burnett-Bowie SM, Saag K, Sebban A, et al. Prediction of changes in bone mineral density in postmenopausal women treated with once-weekly bisphosphonates. *J Clin Endocrinol Metab* 2009;94:1097-1103. doi: 10.1210/jc.2008-1122.
20. Bauer DC, Black DM, Bouxsein ML, et al. Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of anti-resorptive drugs: a meta-regression. *J Bone Miner Res* 2018;33:634-642. doi: 10.1002/jbmr.3355.
21. Eastell R, Black DM, Lui LY, et al. Treatment-related changes in bone turnover and fracture risk reduction in clinical trials of antiresorptive drugs: proportion of treatment effect explained. *J Bone Miner Res* 2021;36:236-243. doi: 10.1002/jbmr.4178.